Free Delivery Over $100
|
|
|||
|
||||
Overview"Neuroscientists are mining nucleic acids, blood, saliva, and brain images in hopes of uncovering biomarkers that could help estimate risk of brain disorders like psychosis and dementia; though the science of bioprediction is young, its prospects are unearthing controversy about how bioprediction should enter hospitals, courtrooms, or state houses. While medicine, law, and policy have established protocols for how presence of disorders should change what we owe each other or who we blame, they have no stock answers for the probabilities that bioprediction offers. The Neuroethics of Biomarkers observes, however, that for many disorders, what we really care about is not their presence per se, but certain risks that they carry. The current reliance of moral and legal structures on a categorical concept of disorder (sick verses well), therefore, obscures difficult questions about what types and magnitudes of probabilities matter. Baum argues that progress in the neuroethics of biomarkers requires the rejection of the binary concept of disorder in favor of a probabilistic one based on biological variation with risk of harm, which Baum names a ""Probability Dysfunction."" This risk-reorientation clarifies practical ethical issues surrounding the definition of mental disorder in the DSM-5 and the nosology of conditions defined by risk of psychosis and dementia. Baum also challenges the principle that the acceptability of bioprediction should depend primarily on whether it is medically useful by arguing that biomarkers can also be morally useful through enabling moral agency, better assessment of legal responsibility, and fairer distributive justice. The Neuroethics of Biomarkers should be of interest to those within neuroethics, medical ethics, and the philosophy of psychiatry." Full Product DetailsAuthor: Matthew L. BaumPublisher: Oxford University Press Inc Imprint: Oxford University Press Inc Dimensions: Width: 23.60cm , Height: 2.00cm , Length: 15.70cm Weight: 0.499kg ISBN: 9780190236267ISBN 10: 0190236264 Pages: 224 Publication Date: 07 April 2016 Audience: Professional and scholarly , Professional & Vocational , Postgraduate, Research & Scholarly Format: Hardback Publisher's Status: Active Availability: To order  Stock availability from the supplier is unknown. We will order it for you and ship this item to you once it is received by us. Table of Contents"Introduction Chapter 1: The Biomedical Promise Of Biomarkers Chapter 2: Bioprediction Of Brain Disorder: Definitions And Scope PART I: REORIENTATION OF THE CONCEPT OF DISORDER Chapter 3:""There Is More Light Here."" Re-Illuminating The Categories Of Mental Chapter 4: The Probability Dysfunction Chapter 5: The Practical Ethics Of Predictive Markers In Diagnosis: Can Risk Banding Address The Ethical Controversy Surrounding ""Psychosis Risk Syndrome"" And ""Preclinical Alzheimer's Disease""? PART II: BIOPREDICTION AND MORAL RESPONSIBILITY Chapter 6: Enhanced Responsibility: Foreseeability And New Obligations To Others Chapter 7: Reduced Responsibility: Distinguishing Conditions In Which Biomarkers Properly Reduce Legal Responsibility PART III: BIOPREDICTION AND SOCIETY Chapter 8: Bioprediction And Priority Conclusion Appendix I Appendix II Appendix III References Index"ReviewsOur society is only beginning to come to grips with the profound implications of using biomarkers as imperfect 'crystal balls' for predicting the development of neurological and psychiatric disease. Dr. Baum's book is an essential guide to the scientific foundations of these tools and the difficult ethical questions that they raise about moral responsibility and priority setting Robert D. Truog, Frances Glessner Lee Professor of Medical Ethics, Anaesthesiology, & Pediatrics and Director of the Center for Bioethics, Harvard Medical School An exciting and comprehensive look at an important topic. Sure to be of interest to scientists and bioethicists working in the area. I. Glenn Cohen, Professor of Law and Faculty Director, Petrie-Flom Center for Health Law Policy, Biotechnology & Bioethics, Harvard Law School < Our society is only beginning to come to grips with the profound implications of using biomarkers as imperfect 'crystal balls' for predicting the development of neurological and psychiatric disease. Dr. Baum's book is an essential guide to the scientific foundations of these tools and the difficult ethical questions that they raise about moral responsibility and priority setting.> Robert D. Truog, Frances Glessner Lee Professor of Medical Ethics, Anaesthesiology, & Pediatrics and Director of the Center for Bioethics, Harvard Medical School < An exciting and comprehensive look at an important topic. Sure to be of interest to scientists and bioethicists working in the area.> I. Glenn Cohen, Professor of Law and Faculty Director, Petrie-Flom Center for Health Law Policy, Biotechnology & Bioethics, Harvard Law School Author InformationMatthew L. Baum, DPhil, is an MD-PhD trainee at Harvard & MIT within the Division of Health Sciences & Technology and the Harvard Program in Neuroscience. He earned a DPhil from Oxford via his work at the Oxford Centre for Neuroethics and the Ethox Center as a Rhodes Scholar. He holds an MSc in Neuroscience from Trinity College Dublin, where he studied as a Mitchell Scholar. He has also served as the student/post-doc representative to the board of the International Neuroethics Society. Tab Content 6Author Website:Countries AvailableAll regions |
||||
